Ganli Pharmaceutical: Ganjing Insulin Injection Receives Drug Registration Approval in Honduras.

Gan Li Pharmaceutical announced that it has recently received approval from the National Drug Supervision and Administration Authority of Honduras to issue the registration certificate for Ganjing insulin injection. This drug is used for the treatment of diabetes, and as of March 31, 2026, the company has cumulatively invested 9.44 billion yuan in research and development expenses for this project. There are approximately 259,000 diabetes patients aged 20-79 in Honduras, with a prevalence of 4.0%. Currently, the main supplier in the region is Sanofi, with global sales of approximately $36.06 billion in 2025. However, there is uncertainty in the sales of the product in Honduras.